About This Calculator
The Nirsevimab (Beyfortus) Dose Calculator provides the recommended dose based on patient weight for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in infants and young children. This guide explains the calculator’s outputs, dosing principles, and administration details according to the FDA-approved prescribing information.
Outputs Explained
After entering the patient’s weight, the tool provides the following critical information:
- Calculated Dose (mg): The total required dose of nirsevimab, which will be either 50 mg or 100 mg.
- Required Product: The specific pre-filled syringe to use. Nirsevimab is supplied in single-dose syringes of 50 mg/0.5 mL (light blue plunger rod) and 100 mg/1 mL (purple plunger rod).
- Administration Route: Confirms the required route, which is always Intramuscular (IM) injection.
How to Use the Calculator
To determine the correct nirsevimab dose, follow these steps:
- Enter Patient Weight: Input the infant’s or child’s current weight into the designated field.
- Select Units: Choose the appropriate unit of weight, either kilograms (kg) or pounds (lbs). The calculator automatically converts pounds to kilograms for the dose calculation.
- Review Results: The tool will instantly display the correct dose and the corresponding pre-filled syringe to administer.
Dosing Overview
Nirsevimab is administered as a single intramuscular (IM) injection once for an RSV season. The dose is determined solely by body weight at the time of administration.
- For infants weighing less than 5 kg (<11 lbs): The recommended dose is 50 mg, administered as one 0.5 mL injection.
- For infants and children weighing 5 kg (11 lbs) or more: The recommended dose is 100 mg, administered as one 1 mL injection.
The recommended injection site is the anterolateral aspect of the thigh.
Switching Medications
Nirsevimab is intended as a single-dose seasonal protection. For infants and children who have previously received palivizumab, nirsevimab can be administered at the start of the next RSV season. There is no established regimen for switching within the same season. If a child remains at high risk, consult clinical guidelines for RSV prevention.
Missed Dose
Nirsevimab is a single-dose prophylactic antibody. A “missed dose” implies that a vulnerable infant did not receive it prior to or during the RSV season. If the RSV season is still active, administer the weight-appropriate dose of nirsevimab as soon as possible to provide protection.
Safety Alerts
Nirsevimab is contraindicated in infants and children with a history of severe hypersensitivity reactions to the active substance or any of its excipients. The most common adverse reactions include rash and injection site reactions (e.g., pain, swelling, redness). Always consult the full prescribing information for a complete list of warnings and precautions before administration.
Frequently Asked Questions (FAQ)
1. What is the exact weight cutoff for the 100 mg dose?
The cutoff is 5 kilograms. An infant or child weighing 5.0 kg or more receives the 100 mg dose.
2. Does the calculator handle weight in pounds (lbs)?
Yes, you can input the weight in either kilograms (kg) or pounds (lbs). The tool automatically converts lbs to kg using the conversion factor 1 kg ≈ 2.20462 lbs.
3. What do the different syringe plunger colors indicate?
The colors help identify the dose strength. The 50 mg / 0.5 mL syringe has a light blue plunger rod, and the 100 mg / 1 mL syringe has a purple plunger rod.
4. Can I administer two 50 mg injections if the 100 mg syringe is not available?
The prescribing information does not recommend administering the 100 mg dose as two separate 50 mg injections. Use the appropriate single pre-filled syringe for the required dose.
5. What is the calculated administration route?
The calculator specifies Intramuscular (IM) injection only, which is the sole FDA-approved route for nirsevimab.
6. Is this calculator suitable for children in their second RSV season?
Yes, the dose calculation is the same for all eligible populations, including children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.
7. Where is the recommended injection site?
The recommended injection site is the anterolateral aspect of the thigh. Gluteal muscle administration is not recommended due to risk of sciatic nerve damage.
8. Does this calculator apply to adults or older children?
No. This tool is specifically for neonates, infants, and children up to 24 months of age according to the approved indications for nirsevimab.
References
- BEYFORTUS (nirsevimab-alip) Prescribing Information. U.S. Food and Drug Administration.
- RSV (Respiratory Syncytial Virus) Prevention. Centers for Disease Control and Prevention.
- Beyfortus (nirsevimab-alip) Official HCP Website. Sanofi & AstraZeneca.
- Beyfortus (nirsevimab) European Public Assessment Report (EPAR). European Medicines Agency.
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com